Targeting tumor invasion in glioblastoma using YAP-TEAD inhibitors
Harnessing YAP-TEAD Activity as Anti-Invasion Therapeutic in Human Glioblastoma
This study is looking at a new way to help people with glioblastoma, a tough type of brain cancer, by using a special drug to improve current treatments and stop the cancer from spreading.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11073426 on NIH RePORTER |
What this research studies
This research focuses on improving treatment for glioblastoma, a type of brain cancer known for its aggressive invasion and recurrence. The team is investigating the role of YAP-TEAD, a protein complex involved in cell movement, to develop therapies that not only stop tumor growth but also prevent its spread. By using a drug called Verteporfin, the researchers aim to enhance the effectiveness of existing treatments and potentially overcome resistance to standard therapies like Temozolomide. Patients with glioblastoma may benefit from this innovative approach that targets the invasive characteristics of their tumors.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with glioblastoma, particularly those experiencing tumor recurrence or resistance to current therapies.
Not a fit: Patients with non-glioblastoma brain tumors or those who are not eligible for glioblastoma treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, reducing tumor invasion and improving patient survival rates.
How similar studies have performed: Previous research has shown promising results in targeting YAP-TEAD pathways in glioblastoma, indicating potential for success in this approach.
Where this research is happening
New York, United States
- Icahn School of Medicine at Mount Sinai — New York, United States (Active)
Researchers
- Principal investigator: Tsankova, Nadejda Mincheva — Icahn School of Medicine at Mount Sinai
- Study coordinator: Tsankova, Nadejda Mincheva
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.